Global Vasomotor Menopausal Symptoms (VMS) Treatment Market – Industry Trends and Forecast to 2030

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class (Antidepressants, Hormone Therapy, Anticonvulsant, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Analysis and Size

As per the North American Menopause Society, up to 75% of females in the U.S. witness hot flashes around menopause. Vasomotor symptoms (VMS), including night sweats and hot flashes, are observed in around 68.5% of women as a result of menopause. The median duration of these symptoms is approximately 4 years, though around 10% of women continue to experience VMS as many as 12 years. The increasing incidence of vasomotor and menopausal symptoms such as hot flashes and night sweats among women during menopausal transition is anticipated to boost the market growth.

Data Bridge Market Research analyses a growth rate in the vasomotor menopausal symptoms (VMS) treatment market in the forecast period 2023-2030. The expected CAGR of vasomotor menopausal symptoms (VMS) treatment market is around 6.20% in the mentioned forecast period. The market was valued at USD 16.71 billion in 2022, and it would grow up to USD 27.03 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Scope and Segmentation

Market Definition

Vasomotor menopausal symptoms (VMS) are a type of rash which affects the area around the mouth and causes inflammation. The rash will extend up the nose or even into the eyes. The common symptom of this condition is a scaly or red bumpy rash. Lesions on darker skin can be hyperpigmented or brown. Antibiotics can be advantageous for a few weeks, whether oral or topically. Azelaic acid is a prescription-only topical medication. When treatment is disturbed, the problem may reoccur, but the same therapy can be restarted as needed.  

Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics

Drivers

• Increase in Menopause Population

The rise in the number of menopausal women which demands treatment for hot flashes and vaginal dryness globally is one of the primary factors pushing the growth of the vasomotor menopausal symptoms (VMS) treatment market. According to a study published in the International Journal of Applied & Basic Medical Research, about 36.7% of women stated hot flashes among 87.7% of women resulting in menopausal symptoms. As per the North American Menopause Society, around 6,000 women in the U.S. reach menopause every day, and about 2 million women per year. The UN data shows around 985 million women aged 50 years and above in 2020. This number is anticipated to reach 1.65 billion by 2050. Thus,this increasing population will rise the different symptoms of menopause and thus will expand the growth of the market.

Opportunities

• Increasing Financial Support by Several Organizations

Numerous public and private organizations are rising their investments in developing novel interventions and treatments which further boost the market growth. Increasing investment in the treatment of menopausal manifestation is anticipated to increase the market. For instance, Bayer AG started the phase III clinical program OASIS in 2021. Under the program, elinzanetant, a dual neurokinin-1,3 receptor antagonist, will be assessed on the standards of efficacy and safety for treating menopausal symptoms such as vasomotor symptoms.  

• Increasing Adoption of OTC Drugs

The market is increasing because of the OTC sale of the products. Patients are slowly adopting OTC products due to their minimal adverse effects. Numerous expansion strategies such as mergers and acquisitions by major market players are leading to the growth of the market. For instance, Bonafide, which is a specialized women’s health company dedicated to providing OTC products, acquired a patented formulation of S-adenosylmethionine in April 2022.

Restraints/Challenges

• Increased Cost of Treatment

The high cost that is needed for numerous treatment methods impedes the market growth. Several market players make some huge investments in manufacturing several advanced treatment techniques to improve the recovery process, and in return, the cost is increased.

This vasomotor menopausal symptoms (VMS) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vasomotor menopausal symptoms (VMS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

The COVID-19 pandemic negatively impacted the market due to the supply chain disruptions and a temporary shutdown of manufacturing facilities. It had majorly impacted the women's mental health, leading to the hormonal imbalance and thus, exaggeration of the vasomotor symptoms. In the post-pandemic era, the increase in the dietary supplements demand because of the shift in consumer trends for nature-based substitutes in place of synthetic pharmaceutical products is anticipated to boost the market in the upcoming years.

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Scope

The vasomotor menopausal symptoms (VMS) treatment market is segmented on the basis of drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antidepressants
• Fluoxetine
• Paroxetine
• Sertraline
• Hormone Therapy
• Anticonvulsant
• Phenytoin
• Phenobarbital
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

 Vasomotor Menopausal Symptoms (VMS) Treatment Regional Analysis/Insights

The vasomotor menopausal symptoms (VMS) treatment market is analyzed and market size insights and trends are provided by drug class, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period because of the wide presence of well-developed healthcare infrastructure and high consumer awareness within the region.

Asia-Pacific is considered to grow over the coming years because of the increasing patient pool, growing investment in the healthcare sector and rising government support.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Vasomotor Menopausal Symptoms (VMS) Treatment Share Analysis

The vasomotor menopausal symptoms (VMS) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vasomotor menopausal symptoms (VMS) treatment market

Key players operating in the vasomotor menopausal symptoms (VMS) treatment market include:

• Zhejiang Huahai Pharmaceutical Co., Ltd (China)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Pfizer Inc (U.S.)
• Hikma Pharmaceutical PLC (U.K)
• Amneal Pharmaceuticals LLC. (U.S.)
• Alembic Pharmaceuticals Limited (India)
• Zydus Group (India)
• Dr. Reddy’s Laboratories Ltd (India)
• Abbvie, Inc (U.S.)
• Sun Pharmaceutical Industries Ltd (India)
• Apotex Inc (Canada)
• Aurobindo Pharma (India)
• Endo Pharmaceuticals plc (Ireland)
• Lupin (India)
• Novartis AG (Switzerland)
• WOCKHARDT (India)